Brigitte Lemyre1,2, Thierry Lacaze-Masmonteil3, Prakesh S Shah4, Jaya Bodani5, Stefanie Doucette3, Michael Dunn6, Deepak Louis7, Luis Monterrosa8, Amit Mukerji9, Georg M Schmölzer10, Balpreet Singh11, Jonathan Wong12, Xiang Y Ye4, Martin Offringa13. 1. Division of Neonatology, Children's Hospital of Eastern Ontario, Ottawa, Canada. blemyre@toh.ca. 2. Department of Obstetrics, Gynecology and Newborn care, The Ottawa Hospital, Ottawa, Canada. blemyre@toh.ca. 3. Department of Pediatrics, Section of Neonatology, Cumming School of Medicine, University of Calgary, Calgary, Canada. 4. Department of Pediatrics, Mount Sinai Hospital and University of Toronto, Toronto, Canada. 5. Regina General Hospital, Department of Pediatrics, College of Medicine, University of Saskatchewan, Regina, Canada. 6. Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Center, Toronto, Canada. 7. Department of Pediatrics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada. 8. Saint John Regional Hospital, Saint John, Canada. 9. Department of Pediatrics, Division of Neonatology, McMaster University, Hamilton, Canada. 10. Division of Neonatology, University of Alberta, Edmonton, Canada. 11. Department of Pediatrics, Dalhousie University, Halifax, Canada. 12. Department of Pediatrics, Division of Neonatology, University of British Columbia, Vancouver, Canada. 13. Department of Pediatrics, University of Toronto, Toronto, Canada.
Abstract
OBJECTIVE: To compare short term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa. STUDY DESIGN: Prospective comparative effectiveness cohort study of infants <32 weeks' gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support. RESULT: 968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission. CONCLUSION: In this pragmatic study, we did not identify any difference in short term outcomes between the groups based on the type of surfactant received.
OBJECTIVE: To compare short term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa. STUDY DESIGN: Prospective comparative effectiveness cohort study of infants <32 weeks' gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support. RESULT: 968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission. CONCLUSION: In this pragmatic study, we did not identify any difference in short term outcomes between the groups based on the type of surfactant received.